Endometrial receptivity determination

A method for treatment comprising implanting an embryo in a human female subject that has been identified as having a receptive endometrium, the method comprising:

• measuring, in a uterine fluid (UF) sample taken from the human female subject, a respective amount of at least three proteins selected from the group consisting of nicotinamide N-methyltransferase encoded by the gene NNMT, neutrophil gelatinase-associated lipocalin encoded by the gene LCN2, progesterone receptor encoded by the gene PGR, sulfate transporter encoded by the gene SLC26A2, sodium-dependent phosphate transport protein 2B encoded by the gene SLC34A2, transcobalamin-1 encoded by the gene TCN1, ectonucleotide pyrophosphatase/phosphodiesterase family member 3 encoded by the gene ENPP3, granulins encoded by the gene GRN, stanniocalcin-1 encoded by the gene STC1, dipeptidyl peptidase 4 encoded by the gene DPP4, myeloperoxidase encoded by the gene MPO, complement decay-accelerating factor encoded by the gene CD55, neutrophil elastase encoded by the gene ELANE, mesothelin encoded by the gene MSLN, cathepsin B encoded by the gene CTSB, ribonuclease T2 encoded by the gene RNASET2, cysteine-rich secretory protein 3 encoded by the gene CRISP3, major vault protein encoded by the gene MVP, matrix metalloproteinase-26 encoded by the gene MMP26, amiloride-sensitive amine oxidase copper-containing encoded by the gene AOC1, and syntenin-2 encoded by the gene SDCBP2;
• comparing the respective amount with a respective control amount of the at least three proteins;
• determining the human female subject has a receptive endometrium by determining that the human female subject is in a mid-secretory (MSE) phase wherein, for each protein of the at least three proteins, the respective amount of the protein is lower than the control amount if the protein is progesterone receptor encoded by the gene PGR and the respective amount of the protein is higher than the control amount if the protein is selected from the group consisting of nicotinamide N-methyltransferase encoded by the gene NNMT, neutrophil gelatinase-associated lipocalin encoded by the gene LCN2, sulfate transporter encoded by the gene SLC26A2, sodium-dependent phosphate transport protein 2B encoded by the gene SLC34A2, transcobalamin-1 encoded by the gene TCN1, ectonucleotide pyrophosphatase/phosphodiesterase family member 3 encoded by the gene ENPP3, granulins encoded by the gene GRN, stanniocalcin-1 encoded by the gene STC1, dipeptidyl peptidase 4 encoded by the gene DPP4, myeloperoxidase encoded by the gene MPO, complement decay-accelerating factor encoded by the gene CD55, neutrophil elastase encoded by the gene ELANE, mesothelin encoded by the gene MSLN, cathepsin B encoded by the gene CTSB, ribonuclease T2 encoded by the gene RNASET2, cysteine-rich secretory protein 3 encoded by the gene CRISP3, major vault protein encoded by the gene MVP, matrix metalloproteinase-26 encoded by the gene MMP26, amiloride-sensitive amine oxidase copper-containing encoded by the gene AOC1, and syntenin-2 encoded by the gene SDCBP2;
• and
• implanting an embryo in the human female subject determined to have a receptive endometrium.